http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9217001-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e56db184ba6168f6f75e6a8e37064fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc1aab0fd9f432e1cd24ab972a89b76c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c793ca6bdaddf347c7c68a9cba53433e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b90c8f67041582d0fc8aa8f34571f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35bce0b8363dc3e87c11597734a15083 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 |
| filingDate | 2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1995eae0dbd9dcb4bcebc41db141326e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ba62c87876814050d659926e8a1f3e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57c9721e3ccf4a12c1adda40bd1c7d78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b257bfc56d64306d87d77e6e76f0926 |
| publicationDate | 2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9217001-B2 |
| titleOfInvention | Crystalline bortezomib process |
| abstract | The present invention provides process for preparation of crystalline Bortezomib (Ia) as its monohydrate which is designated as crystalline Form-SB n nand characterized by having water content ranging between 3.5-6.0% w/w; X-ray powder diffraction pattern comprising characteristic 2θ° peaks selected from the XRPD peak set of 5.6, 7.5, 9.8, 10.2, 11.3, 15.1, 18.0, 20.5, 21.5 and 23.6±0.20 2θ°, wherein peaks at 9.8 and 11.39±0.20 2θ° are un-split and 100% intensity peak is present at 5.6±0.20 2θ°, DSC isotherm comprising the endothermic peaks ranging between 45 to 60° C. (Peak-1) and 175 to 185° C. (Peak-2) and IR absorption characteristic peaks approximately at 3387 cm −1 , 3304 cm −1 , 2953 cm −1 , 2927 cm −1 , 2868 cm −1 , 1627 cm −1 , 1455 cm −1 , 1400 cm −1 , 1201 cm −1 , 1150 cm −1 , 1020 cm −1 , 747 cm −1 and 702 cm −1 and Raman absorption spectra having characteristic peaks approximately at 3066 cm −1 , 1583 cm −1 , 1528 cm −1 , 1281 cm −1 , 1213 cm −1 , 1035 cm −1 , 1022 cm −1 and 1004 cm −1 . The invention also provides the use of said crystalline Form-SB as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023002418-A1 |
| priorityDate | 2012-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.